Respiratory failure & ventilation

Electrical impedance tomography-guided positive end-expiratory pressure (PEEP) and mortality of patients with the acute respiratory distress syndrome: The EITVent randomized clinical trial

Am J Respir Crit Care MedPublished Randomised controlled trial

  • terminated early for futility

Authors' conclusion

In patients with moderate to severe ARDS, EIT-guided PEEP did not significantly reduce 28-day mortality compared with the lower PEEP/FiO2 table strategy.

Study context

Population
Adults with moderate to severe acute respiratory distress syndrome (ARDS), 5 sites in China, February 2022 to June 2023all completed follow-up
Participants
190 adults
Comparison
Electrical impedance tomography (EIT)-guided PEEP vs lower PEEP/FiO2 table
Primary endpoint
28-day mortality
Follow-up
28 days
Methodological detailsmulticentre, pre-planned interim analysis
  • Multicentre
  • Pre-planned interim analysis

Primary result

As reported in the abstract

Hazard ratio

0.96

95% CI 0.65–1.41

P = 0.821

Events by treatment group

EIT-guided PEEP vs Lower PEEP/FiO2 table
HR 0.96 (95% CI 0.65–1.41); P = 0.821

Further findings

OutcomeEIT-guided PEEPLower PEEP/FiO2 tableHR (95% CI)P value
28-day mortality, patients with higher lung recruitability (recruitment-inflation ratio) (subgroup)35.6% · 16 of 4560.0% · 27 of 450.49 (0.26–0.91)P = 0.024

PEEP levels during the first 7 days

PEEP levels didn't differ between groups (difference in marginal means 0.2 [SE 0.1]; P = .187)

Ventilator-free days and other secondary clinical outcomes

Did not differ

Safety

Safety outcomes

Did not differ between groups

Original publication

Electrical impedance tomography-guided PEEP and mortality of patients with the acute respiratory distress syndrome: The EITVent randomized clinical trial. Am J Respir Crit Care Med. Published 23 January 2026. doi:10.1093/ajrccm/aamaf125

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.